ArticleCurrent drug targets2026
Possible Thrombus-clearing Mechanism and Modification Suggestion of β-sitosterol.
Article in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThrombin (THR) is a key therapeutic target for anticoagulant therapy, yet the mechanism of β-sitosterol, a natural compound with antithrombotic potential, remains unclear.
methodsThis study integrated AI-driven structural alignment, molecular docking, Molecular Dynamics (MD) simulations, binding free energy calculation, and Density Functional Theory (DFT) calculations to elucidate the recognition mechanism between THR and β-sitosterol.
resultsSimulations revealed that β-sitosterol binding is stabilized primarily by hydrophobic and van der Waals interactions, leading to the closure of the active site and conformational changes in the EF_loop (i.e., γ-loop). The large conformational changes within EF_Loop may be dominated by weak interactions between W168/ P184/ Q183/ S185 and the ligand β-sitosterol. Based on these insights, a series of novel sterol derivatives was designed with improved binding affinity and predicted antithrombotic activity, as indicated by the lowest binding free energy. DISCUSSION: This study not only reveals molecular recognition and inhibitory mechanism of β- sitosterol at the atomic level, but also provides suggestions for structural optimization of novel inhibitors against human thrombin. Future work should include in vitro binding assays and in vivo functional studies to confirm the inhibitory activity.
conclusionThe conformational change of EF_loop with the recognition of β-sitosterol effectively occludes the catalytic site, thereby impairing thrombin's proteolytic activity. Among 13 designed sterol derivatives, the compound d3 was identified as a promising inhibitor with excellent ADMET properties. This work provides an anticoagulant mechanism for the dynamic identification of β- sitosterol and supports the rational design of allosteric THR inhibitors.
Indexed as
Identifiers
41510722What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.